". Der Spiegel (in German). ISSN 2195-1349. Retrieved 10 October 2022. The White House (26 April 2022). "FACT SHEET: Biden Administration Increases Access to COVID-19 Treatments and Boosts Patient and Provider Awareness". The White House...
EUA Fact Sheet for HCPs About Pfizer: Breakthroughs That Change Patients’ Lives At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discov...
Revises 2023 Adjusted(2)Diluted EPS Guidance(1)to $1.45 to $1.65 to Account for Lower Expected Revenues for COVID Products and Inventory Write-Offs, Partially Offset by $1.0 Billion of Anticipated 2023 Cost Reductions Pfizer to hold analyst and investor call at 8 a.m. EDT M...
参考文献 [1] Fact Sheet for Healthcare Providers: Emergency Use Authorization for Paxlovid, FDA. [2]https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html [3]https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care /underlyingconditions.html ...
5.US Food and Drug Administration. Fact Sheet for Healthcare Providers: Emergency Use Authorization for Paxlovid. (2023). Accessed: January 6, 2023: https://www.fda.gov/media/155050/download.
3. FACT SHEET FOR HEALTHCARE PROVIDERS: EMERGENCY USE AUTHORIZATION FOR PAXLOVIDTM. Pfizer. 7 March 2022. 4. Cully M. A tale of two antiviral targets - and the COVID-19 drugs that bind them. Nat Rev Drug Discov. 2022;21(1):3-5. ...
It’s worth noting that Paxlovid is still being studied, so it is possible that all of the risks are not yet known. (TheFDA has provided a fact sheet on Paxlovidwith a full list of known side effects.) 值得注意的是,Paxlovid仍在研究阶段,因此所有的风险可能仍然处于未知状态。(FAD已经提供...
2023年1月8日,2022年国家医保药品目录谈判工作正式结束,美国辉瑞高效新冠阻断药物帕罗韦德/帕克洛维(Paxlovid)因报价过高遗憾“出局”,这就意味着目前纳入临时医保的帕罗韦德/帕克洛维将在今年3月31日之后只能全额自费购买,无法享受报销优惠。 2021年12月,美国食品药品监督管理(FDA)局发布了辉瑞公司Paxlovid(nirmatrevi...
最近，辉瑞新冠抗病毒口服药Paxlovid引发热议，该药为含奈玛特韦/利托那韦（两种蛋白酶抑制剂）片剂的...
Consult Table 1 of the Fact Sheet for Healthcare Providers for clinically significant drug interactions, including contraindicated drugs. Drugs listed in Table 1 are a guide and not considered a comprehensive list of all possible drugs that may interact with PAXLOVID. Consi...